Back to results
US 2015/0306224 A1Published application
Formulation of human antibodies for treating tnf-alpha associated disorders
AssigneeAbbVie Biotechnology Ltd.
InventorsHans-Juergen Krause, Lisa Baust, Michael Dickes
Life of this patent
Estimating the term…
Abstract
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
Claims30
A stable liquid aqueous pharmaceutical formulation comprising
- (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody at a concentration of 50 mg/ml,
- (b) a polyol,
- (c) a polysorbate, and
- (d) a buffer system comprising an organic acid and having a pH of 4 to 8,
- wherein the antibody is D2E7, and
- wherein the formulation is suitable for subcutaneous injection.
3 more elements
Dependencies are inferred from the claim text.